CERTIFICATE OF MAILING

I hereby certain his correspondence is being deposited with the United States Postal Service irst class mail in an envelope addressed to: Assistant Commission for Patents, Arlington, VA 22202, on the date appearing below.

ELI LILLY AND COMPANY Date

PATENT APPLICATIO

Confirm. No.:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant Mark Laurence Brader

Serial No. : 10/010,038

Filed : December 6, 2001 8529

For INSOLUBLE INSULIN COMPOSITIONS Group Art Unit:

1653

Docket No. : X-11232B

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Arlington, VA 22202

Sir:

As a means of complying with the duty of disclosure, Applicant submits an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicant submits that no fee is required.

The present application is a continuation of application Ser. No. 09/761,903. Listed on the Form PTO-1449 as document CH are the pending claims for co-pending application Ser. No. 09/761,903. A copy of the pending claims for application Ser. No. 09/761,903 is provided herewith.

Application Ser. No. 09/761,903 is a divisional of application Ser. No. 09/177,685, which issued as U.S. Patent No. 6,268,335, which is listed on the PTO-1449 as document AC.

Applicant requests consideration of this information.

Respectfully submitted,

rant/E. Reed

Attorney for Applicant Registration No. 41,264 Phone: 317-276-1664

Eli Lilly and Company Patent Division/GER Lilly Corporate Center Indianapolis, IN 46285

Marcle 27, 2002

FORM PTO 1449 (modified)

Atty. Docket No. Serial No 10/010,038

Applicants
Mark Laurence Brader

Filing Date December 6, 2001

Framiner

Date Name Class Sub Filing Pate

		Eth. we	U.S. PATE	T DOCUMENTS	<u> </u>		
Examiner Initial		Number	Date	Name	Class	Sub- class	Filingate II Appropriate
	AA	5,840,680	Nov. 24, 1998	Balschmidt	514	3	Dec. 11, 1996
	AB	4,946,828	Aug. 7, 1990	Markussen	514	3	Jul. 20, 1987
	AC	6,268,335	Jul. 31, 2001	Brader .	514	3	Oct. 22, 1998
	AD	5,750,497	May 12, 1998	Havelund, et al.	514	3	Mar. 8, 1995
	AE	6,011,007	Jan. 4, 2000	Havelund, et al.	514	3	Nov. 20, 1997
	AF	3,868,357	Feb. 25, 1975	Smyth, et al.	260	112.7	Jan. 26, 1972
	AG	2,849,370	Aug. 26, 1958	Petersen, et al.	167	75	May 28, 1954
	AH	3,060,093	Oct. 23, 1962	Poulsen, et al.	167	75	Jul. 15, 1958
	AI	3,864,325	Feb. 4, 1975	Smyth	260	112.7	Nov. 13, 1972
	AJ	3,868,356	Feb. 25, 1975	Smyth	260	112.7	Jan. 26, 1972
	AK	3,869,437	Mar. 4, 1975	Lindsay, et al.	260	112.7	Aug. 21, 1973
	AL	3,950,517	Apr. 13, 1976	Lindsay, et al.	424	178	Dec. 6, 1974
	AM	5,461,031	Oct. 24, 1995 Aug. 20, 1996	DeFelippis	514	4	Jun. 16, 1994
	AN	5,650,486	Jul. 22, 1997	Balschmidt DeFelippis	514	3	Sep. 28, 1993
	AP	5,747,642	May 5, 1998	DeFelippis	530	305	Jun. 1, 1995 Jun. 1, 1995
	AO	4,959,351	Sep. 25, 1990	Grau	514	304	
	AQ	5,948,751		Kimer, et al.		4	Jul. 27, 1984
	AS	6,127,334	Sep. 7, 1999 Oct. 3, 2000	Kimer, et al.	514	3	Jun. 19, 1997 Nov. 24, 1998
	AT	6,051,551	Apr. 18, 2000	Hughes, et al.	514	3	
	AU	6,335,316	Jan. 1, 2002				Oct. 29, 1998
	AU	0,333,316	Juli. 1, 2002	Hughes, et al.	514	3	Mar. 10, 2000

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXAMINER

.

DATE CONSIDERED

**

FORM PTO	1449	(modified)		Atty. Docket No. X-11232B	Seria		王	Α	
TMFORMATI	NATION DISCLOSURE CITATION Applicant								
0				Mark Laurence Brad		c		0	
				Filing Date December 6, 2001	Group 1653		60	200	
			FOREIGN	PATENT DOCUMENTS			25		
		Document Number	Date	Country	Class	Sub- class	Træs	lation	
							yes	no	
	BA	EP 0375437 27	Jun 1990	EP					
	BB	WO 95/00550 05	Jan 1995	WIPO					
**************************************	BC	WO 95/07931 23	Mar 1995	WIPO					
	BD	WO 98/34953 13	Aug 1998	WIPO				<u> </u>	
	BE	WO 96/29344 26	Sep 1996	WIPO					
	BF	WO 97/48413 24	Dec 1997	WIPO					
			OTI	HER DOCUMENTS		·	·	· 1	
	CA	of Basic Pr	oteins a	e, et al., "Insulin nd Peptides", Biochi	m. Biophy	s. Acta,	n the P 214:14	resence	
	CB	(1970), Elsevier Science, Amsterdam, The Netherlands Scott and Fisher, "Studies on Insulin With Protamaine", J. Pha: Exp. Ther., 58:78-92 (May 1936), American Society for Pharmacol Experimental Therapeutics, Bethesda, MD							
	cc	Hagedorn, e 180 (1936),	sn., 106:177-						
	CD	Krayenbuhl and Rosenberg, "Crystalline Protamine Insulin", in: Steno, Mem. Hosp. Nor. Insulinlab., 1:60-73 (1946), Copenhagen Denmark Myers, S.R., et al., "Acylation of Human Insulin With Palmitic Extends the Time Action of Human Insulin in Diabetic Dogs", Di							
	CE								
	ļ. <u></u> .	46:637-642	(April 1	997), American Diabe	tes Assoc.	iation,	Alexand	ria, VA	
	CF	Hashimoto, M., et al., "Synthesis of Palmitoyl Derivatives of Instand Their Biological Activities", Pharmaceut. Res., 6:171-176 (19) American Association of Pharmaceutical Scientists, Arlington, VA Whittingham, et al., "Crystal Structure of Prolonged-Acting Insuluith Albumin-Binding Properties", Biochemistry, Vol. 36, No. 10, p							
	CG								
	CH			97), American Chemic 162 for U.S. Applica				DC	
	-								
	 								
	ļ								
	ļ								
,									
EXAMINER				DATE CONSIDER	ED			·	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

}